Država: Ciper
Jezik: grščina
Source: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
BRIMONIDINE TARTRATE
DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629
S01EA05
BRIMONIDINE
2MG/ML
EYE DROPS, SOLUTION
BRIMONIDINE TARTRATE (8000001808) 2MG
OCULAR USE
Εθνική Διαδικασία
BRIMONIDINE
Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 1 BOTTLE X 5ML (310014001) 5 MILLILITRE - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Edecol 2 mg/ml Eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 2.0 mg brimonidine tartrate. Excipient(s) with known effect: Contains benzalkonium chloride 0.05 mg/ml. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, solution. Edecol 2 mg/ml eye drops, solution is a clear and slightly greenish-yellow solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. As monotherapy in patients in whom topical beta-blocker therapy is contraindicated. As adjunctive therapy to other intraocular pressure lowering medications when the target IOP is not achieved with a single agent (see Section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Recommended dosage in adults (including the elderly)_ The recommended dose is one drop of Edecol in the affected eye(s) twice daily, approximately 12 hours apart. No dosage adjustment is required for the use in elderly patients. As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctal occlusion) for one minute. This should be performed immediately following the instillation of each drop. If more than one topical ophthalmic drug is to be used, the different drugs should be instilled 5-15 minutes apart. 1 _Use in renal and hepatic impairment_ Brimonidine tartrate has not been studied in patients with hepatic or renal impairment (see section 4.4). _Use in paediatric subjects_ No clinical studies have been performed in adolescents (12 to 17 years). Edecol is not recommended for use in children below 12 years and is contraindicated in neonates and infants (less than 2 years of age) (see sections 4.3, 4.4 and 4.9). It is known that severe adverse reactions can occur in neonates. The safety and efficacy of brimonidine tartrate have not been esta Preberite celoten dokument